Role of SKP1-CUL1-F-Box-Protein (SCF) E3 Ubiquitin Ligases in Skin Cancer

Journal of Genetics and Genomics

Volumn 40, Issue 3, 2013, Pages 97-106

  Xie, Chuan Ming ^b   Wei, Wenyi ^c   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Carcinogenesis; F box proteins; RING proteins; SCF E3 ligases; Skin; Ubiquitin ligases

Indexed keywords

ADAPTOR PROTEIN; CULLIN; CULLIN 1; F BOX PROTEIN; I KAPPA B KINASE ALPHA; PROTEIN C JUN; PROTEIN P27; PROTEIN SKP 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CANCER SURVIVAL; HUMAN; MELANOCYTIC NEVUS; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; ULTRAVIOLET B RADIATION;

ANIMALS; CARRIER PROTEINS; CELL CYCLE PROTEINS; CULLIN PROTEINS; F-BOX PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINOCYTES; PROTEOLYSIS; S-PHASE KINASE-ASSOCIATED PROTEINS; SKIN; SKIN NEOPLASMS; UBIQUITIN-PROTEIN LIGASES; ULTRAVIOLET RAYS;

EID: 84875498138     PISSN: 16738527     EISSN: 18735533     Source Type: Journal    
DOI: 10.1016/j.jgg.2013.02.001     Document Type: Review

References (123)

1. Aghajan M., Jonai N., Flick K., Fu F., Luo M., Cai X., Ouni I., Pierce N., Tang X., Lomenick B., Damoiseaux R., Hao R., Del Moral P.M., Verma R., Li Y., Li C., Houk K.N., Jung M.E., Zheng N., Huang L., Deshaies R.J., Kaiser P., Huang J. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 2010, 28:738-742.
2. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., Cepeda D., Fiegl H., Dafou D., Marth C., Mueller-Holzner E., Corcoran M., Dagnell M., Nejad S.Z., Nayer B.N., Zali M.R., Hansson J., Egyhazi S., Petersson F., Sangfelt P., Nordgren H., Grander D., Reed S.I., Widschwendter M., Sangfelt O., Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007, 67:9006-9012.
3. Alonso S.R., Ortiz P., Pollan M., Perez-Gomez B., Sanchez L., Acuna M.J., Pajares R., Martinez-Tello F.J., Hortelano C.M., Piris M.A., Rodriguez-Peralto J.L. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 2004, 164:193-203.
4. Anzi S., Finkin S., Shaulian E. Transcriptional repression of c-Jun's E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal. 2008, 20:862-871.
5. Arbeit J.M., Munger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 1994, 68:4358-4368.
6. Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., Elledge S.J. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996, 86:263-274.
7. Bai J., Zhou Y., Chen G., Zeng J., Ding J., Tan Y., Zhou J., Li G. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum. Pathol. 2011, 42:375-383.
8. Bergers G., Hanahan D., Coussens L.M. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 1998, 42:995-1002.
9. Bhatia N., Demmer T.A., Sharma A.K., Elcheva I., Spiegelman V.S. Role of beta-TrCP ubiquitin ligase receptor in UVB mediated responses in skin. Arch. Biochem. Biophys. 2011, 508:178-184.
10. Bhatia N., Demmer T.A., Spiegelman V.S. Inhibition of beta-TrCP function potentiates UVB-induced apoptosis in hTERT-immortalized normal human keratinocytes. Photochem. Photobiol. 2008, 84:376-381.
11. Bhatia N., Herter J.R., Slaga T.J., Fuchs S.Y., Spiegelman V.S. Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappaB. Oncogene 2002, 21:1501-1509.
12. Bhatia S., Afanasiev O., Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr. Oncol. Rep. 2011, 13:488-497.
13. Brownell J.E., Sintchak M.D., Gavin J.M., Liao H., Bruzzese F.J., Bump N.J., Soucy T.A., Milhollen M.A., Yang X., Burkhardt A.L., Ma J., Loke H.K., Lingaraj T., Wu D., Hamman K.B., Spelman J.J., Cullis C.A., Langston S.P., Vyskocil S., Sells T.B., Mallender W.D., Visiers I., Li P., Claiborne C.F., Rolfe M., Bolen J.B., Dick L.R. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 2010, 37:102-111.
14. Carrano A.C., Eytan E., Hershko A., Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol. 1999, 1:193-199.
15. Chen G., Cheng Y., Martinka M., Li G. Cul1 expression is increased in early stages of human melanoma. Pigment Cell Melanoma Res. 2010, 23:572-574.
16. Chen G., Cheng Y., Zhang Z., Martinka M., Li G. Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS ONE 2011, 6:e17578.
17. Chen G., Li G. Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int. J. Oncol. 2010, 37:1339-1344.
18. Chen Q., Xie W., Kuhn D.J., Voorhees P.M., Lopez-Girona A., Mendy D., Corral L.G., Krenitsky V.P., Xu W., Moutouh-de Parseval L., Webb D.R., Mercurio F., Nakayama K.I., Nakayama K., Orlowski R.Z. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008, 111:4690-4699.
19. Chen Z.J., Sun L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol. Cell 2009, 33:275-286.
20. Clifford S.C., Astuti D., Hooper L., Maxwell P.H., Ratcliffe P.J., Maher E.R. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 2001, 20:5067-5074.
21. Colburn N.H., Former B.F., Nelson K.A., Yuspa S.H. Tumour promoter induces anchorage independence irreversibly. Nature 1979, 281:589-591.
22. Coussens L.M., Hanahan D., Arbeit J.M. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am. J. Pathol. 1996, 149:1899-1917.
23. Curiel-Lewandrowski C., Yamasaki H., Si C.P., Jin X., Zhang Y., Richmond J., Tuzova M., Wilson K., Sullivan B., Jones D., Ryzhenko N., Little F., Kupper T.S., Center D.M., Cruikshank W.W. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J. Clin. Invest. 2011, 121:4838-4849.
24. D'Andrea A., Pellman D. Deubiquitinating enzymes: a new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 1998, 33:337-352.
25. Deshaies R.J., Joazeiro C.A. RING domain E3 ubiquitin ligases. Annu. Rev. Biochem. 2009, 78:399-434.
26. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006, 314:467-471.
27. Duan H., Wang Y., Aviram M., Swaroop M., Loo J.A., Bian J., Tian Y., Mueller T., Bisgaier C.L., Sun Y. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol. Cell Biol. 1999, 19:3145-3155.
28. Duan S., Skaar J.R., Kuchay S., Toschi A., Kanarek N., Ben-Neriah Y., Pagano M. mTOR generates an auto-amplification loop by triggering the betaTrCP- and CK1alpha-dependent degradation of DEPTOR. Mol. Cell 2011, 44:317-324.
29. Einspahr J.G., Bowden G.T., Alberts D.S. Skin cancer chemoprevention: strategies to save our skin. Recent Results Cancer Res. 2003, 163:151-164. discussion 264-266.
30. Erickson L.A., Papotti M., Volante M., Jin L., Lewis J.E., Lloyd R.V. Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. Endocr. Pathol. 2003, 14:221-229.
31. Frescas D., Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat. Rev. Cancer 2008, 8:438-449.
32. Fuchs S.Y., Spiegelman V.S., Kumar K.G. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036.
33. Gao D., Inuzuka H., Tan M.K., Fukushima H., Locasale J.W., Liu P., Wan L., Zhai B., Chin Y.R., Shaik S., Lyssiotis C.A., Gygi S.P., Toker A., Cantley L.C., Asara J.M., Harper J.W., Wei W. mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol. Cell 2011, 44:290-303.
34. Gu Q., Bowden G.T., Normolle D., Sun Y. SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IkappaB-alpha/NF-kappaB. J. Cell Biol. 2007, 178:1009-1023.
35. Gu Q., Tan M., Sun Y. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. Cancer Res. 2007, 67:3616-3625.
36. Hartwell L.H., Mortimer R.K., Culotti J., Culotti M. Genetic control of the cell division cycle in yeast: V. Genetic analysis of cdc mutants. Genetics 1973, 74:267-286.
37. He H., Gu Q., Zheng M., Normolle D., Sun Y. SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27. Carcinogenesis 2008, 29:858-865.
38. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
39. Ikeda F., Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep. 2008, 9:536-542.
40. Ishikawa Y., Hosogane M., Okuyama R., Aoyama S., Onoyama I., Nakayama K.I., Nakayama K. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch. Oncogene 2012, 10.1038/onc.2012.213.
41. Jia L., Li H., Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011, 13:561-569.
42. Jia L., Soengas M.S., Sun Y. ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 2009, 69:4974-4982.
43. Jia L., Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr. Cancer Drug Targets 2011, 11:347-356.
44. Jia L., Yang J., Hao X., Zheng M., He H., Xiong X., Xu L., Sun Y. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin. Cancer Res. 2010, 16:814-824.
45. Jin J., Cardozo T., Lovering R.C., Elledge S.J., Pagano M., Harper J.W. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004, 18:2573-2580.
46. Kamura T., Conrad M.N., Yan Q., Conaway R.C., Conaway J.W. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev. 1999, 13:2928-2933.
47. Katagiri Y., Hozumi Y., Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J. Dermatol. Sci. 2006, 42:215-224.
48. Kipreos E.T., Lander L.E., Wing J.P., He W.W., Hedgecock E.M. Cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996, 85:829-839.
49. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 2007, 64:2746-2762.
50. Koike J., Sagara N., Kirikoshi H., Takagi A., Miwa T., Hirai M., Katoh M. Molecular cloning and genomic structure of the betaTRCP2 gene on chromosome 5q35.1. Biochem. Biophys. Res. Commun. 2000, 269:103-109.
51. Leiter U., Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer-the role of sunlight. Adv. Exp. Med. Biol. 2008, 624:89-103.
52. Li Q., Murphy M., Ross J., Sheehan C., Carlson J.A. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J. Cutan. Pathol. 2004, 31:633-642.
53. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., Cordon-Cardo C., Teruya-Feldstein J., Pandolfi P.P. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
54. Lin J.J., Milhollen M.A., Smith P.G., Narayanan U., Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 2010, 70:10310-10320.
55. Liu J., Suresh Kumar K.G., Yu D., Molton S.A., McMahon M., Herlyn M., Thomas-Tikhonenko A., Fuchs S.Y. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene 2007, 26:1954-1958.
56. Liu L., Lee S., Zhang J., Peters S.B., Hannah J., Zhang Y., Yin Y., Koff A., Ma L., Zhou P. CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis. Mol. Cell 2009, 34:451-460.
57. Luo Z., Yu G., Lee H.W., Li L., Wang L., Yang D., Pan Y., Ding C., Qian J., Wu L., Chu Y., Yi J., Wang X., Sun Y., Jeong L.S., Liu J., Jia L. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 2012, 72:3360-3371.
58. Mao J.H., Perez-Losada J., Wu D., Delrosario R., Tsunematsu R., Nakayama K.I., Brown K., Bryson S., Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432:775-779.
59. Margottin F., Bour S.P., Durand H., Selig L., Benichou S., Richard V., Thomas D., Strebel K., Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1998, 1:565-574.
60. Mathias N., Johnson S.L., Winey M., Adams A.E., Goetsch L., Pringle J.R., Byers B., Goebl M.G. Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins. Mol. Cell. Biol. 1996, 16:6634-6643.
61. Miele L. Notch signaling. Clin. Cancer Res. 2006, 12:1074-1079.
62. Milhollen M.A., Narayanan U., Soucy T.A., Veiby P.O., Smith P.G., Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 2011, 71:3042-3051.
63. Milhollen M.A., Traore T., Adams-Duffy J., Thomas M.P., Berger A.J., Dang L., Dick L.R., Garnsey J.J., Koenig E., Langston S.P., Manfredi M., Narayanan U., Rolfe M., Staudt L.M., Soucy T.A., Yu J., Zhang J., Bolen J.B., Smith P.G. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-kappaB-dependent lymphoma. Blood 2010, 116:1515-1523.
64. Mo J.S., Kim M.Y., Han S.O., Kim I.S., Ann E.J., Lee K.S., Seo M.S., Kim J.Y., Lee S.C., Park J.W., Choi E.J., Seong J.Y., Joe C.O., Faessler R., Park H.S. Integrin-linked kinase controls Notch1 signaling by down-regulation of protein stability through Fbw7 ubiquitin ligase. Mol. Cell. Biol. 2007, 27:5565-5574.
65. Munger K., Scheffner M., Huibregtse J.M., Howley P.M. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992, 12:197-217.
66. Nai G., Marques M. Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. Pathol. Res. Pract. 2011, 207:174-181.
67. Nakayama K.I., Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat. Rev. Cancer 2006, 6:369-381.
68. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5:596-613.
69. Nawrocki S.T., Griffin P., Kelly K.R., Carew J.S. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin. Investig. Drugs 2012, 21:1563-1573.
70. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., Hui C.C., Clevers H., Dotto G.P., Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003, 33:416-421.
71. Ohta T., Michel J.J., Schottelius A.J., Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol. Cell 1999, 3:535-541.
72. Orlicky S., Tang X., Neduva V., Elowe N., Brown E.D., Sicheri F., Tyers M. An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat. Biotechnol. 2010, 28:733-737.
73. Penin R.M., Fernandez-Figueras M.T., Puig L., Rex J., Ferrandiz C., Ariza A. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod. Pathol. 2002, 15:1227-1235.
74. Perez-Losada J., Wu D., DelRosario R., Balmain A., Mao J.H. Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. PLoS ONE 2012, 7:e31301.
75. Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137:873-886.
76. Reifenberger J., Knobbe C.B., Wolter M., Blaschke B., Schulte K.W., Pietsch T., Ruzicka T., Reifenberger G. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int. J. Cancer 2002, 100:549-556.
77. Ribatti D., Nico B., Crivellato E., Roccaro A.M., Vacca A. The history of the angiogenic switch concept. Leukemia 2007, 21:44-52.
78. Rosso S., Zanetti R., Pippione M., Sancho-Garnier H. Parallel risk assessment of melanoma and basal cell carcinoma: skin characteristics and sun exposure. Melanoma Res. 1998, 8:573-583.
79. Saladi R.N., Persaud A.N. The causes of skin cancer: a comprehensive review. Drugs Today (Barc) 2005, 41:37-53.
80. Salehi-Tabar R., Nguyen-Yamamoto L., Tavera-Mendoza L.E., Quail T., Dimitrov V., An B.S., Glass L., Goltzman D., White J.H. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proc. Natl. Acad. Sci. USA 2012, 109:18827-18832.
81. Salon C., Brambilla E., Brambilla C., Lantuejoul S., Gazzeri S., Eymin B. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J. Pathol. 2007, 213:303-310.
82. Sarikas A., Hartmann T., Pan Z.Q. The cullin protein family. Genome Biol. 2011, 12:220.
83. Schmid T., Jansen A.P., Baker A.R., Hegamyer G., Hagan J.P., Colburn N.H. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res. 2008, 68:1254-1260.
84. Seol J.H., Feldman R.M.R., Zachariae W.Z., Shevchenko A., Correll C.C., Lyapina S., Chi Y., Galova M., Claypool J., Sandmeyer S., Nasmyth K., Shevchenko A., Deshaies R.J. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev. 1999, 13:1614-1626.
85. Serres M.P., Zlotek-Zlotkiewicz E., Concha C., Gurian-West M., Daburon V., Roberts J.M., Besson A. Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro. Oncogene 2011, 30. 2846-2058.
86. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
87. Sistrunk C., Macias E., Nakayama K., Kim Y., Rodriguez-Puebla M.L. Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium. Am. J. Pathol. 2011, 178:2470-2477.
88. Skaar J.R., D'Angiolella V., Pagan J.K., Pagano M. SnapShot: F box proteins II. Cell 2009, 137:1358 e1.
89. Soucy T.A., Dick L.R., Smith P.G., Milhollen M.A., Brownell J.E. The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy. Genes Cancer 2010, 1:708-716.
90. Soucy T.A., Smith P.G., Milhollen M.A., Berger A.J., Gavin J.M., Adhikari S., Brownell J.E., Burke K.E., Cardin D.P., Critchley S., Cullis C.A., Doucette A., Garnsey J.J., Gaulin J.L., Gershman R.E., Lublinsky A.R., McDonald A., Mizutani H., Narayanan U., Olhava E.J., Peluso S., Rezaei M., Sintchak M.D., Talreja T., Thomas M.P., Traore T., Vyskocil S., Weatherhead G.S., Yu J., Zhang J., Dick L.R., Claiborne C.F., Rolfe M., Bolen J.B., Langston S.P. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009, 458:732-736.
91. Sumimoto H., Hirata K., Yamagata S., Miyoshi H., Miyagishi M., Taira K., Kawakami Y. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int. J. Cancer 2006, 118:472-476.
92. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 2006, 8:645-654.
93. Sun Y., Hegamyer G., Colburn N.H. Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res. 1994, 54:1139-1144.
94. Sun Y., Li H. Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 2012, 10.1007/s13238-012-2105-7.
95. Sun Y., Tan M., Duan H., Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid. Redox Signal. 2001, 3:635-650.
96. Sutterluty H., Chatelain E., Marti A., Wirbelauer C., Senften M., Muller U., Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat. Cell Biol. 1999, 1:207-214.
97. Swaroop M., Bian J., Aviram M., Duan H., Bisgaier C.L., Loo J.A., Sun Y. Expression, purification, and biochemical characterization of SAG, a RING finger redox sensitive protein. Free Radic. Biol. Med. 1999, 27:193-202.
98. Swaroop M., Wang Y., Miller P., Duan H., Jatkoe T., Madore S., Sun Y. Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: Chip profiling implicates its role in cell cycle regulation. Oncogene 2000, 19:2855-2866.
99. Swords R.T., Kelly K.R., Smith P.G., Garnsey J.J., Mahalingam D., Medina E., Oberheu K., Padmanabhan S., O'Dwyer M., Nawrocki S.T., Giles F.J., Carew J.S. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010, 115:3796-3800.
100. Tan M., Gallegos J.R., Gu Q., Huang Y., Li J., Jin Y., Lu H., Sun Y. SAG/ROC-SCFbeta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. Neoplasia 2006, 8:1042-1054.
101. Tan M., Gu Q., He H., Pamarthy D., Semenza G.L., Sun Y. SAG/ROC2/RBX2 is a HIF-1 target gene that promotes HIF-1alpha ubiquitination and degradation. Oncogene 2008, 27:1404-1411.
102. Tan M., Li Y., Yang R., Xi N., Sun Y. Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS ONE 2011, 6:e27726.
103. Tan M., Zhao Y., Kim S.J., Liu M., Jia L., Saunders T.L., Zhu Y., Sun Y. SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev. Cell 2011, 21:1062-1076.
104. Tan M., Zhu Y., Kovacev J., Zhao Y., Pan Z.Q., Spitz D.R., Sun Y. Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-kB activation in mouse embryonic stem cells. Free Radic. Biol. Med. 2010, 49:976-983.
105. Tan P., Fuchs S.Y., Chen A., Wu K., Gomez C., Ronai Z., Pan Z.-Q. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IkBa. Mol. Cell 1999, 3:527-533.
106. skp2 complex through phosphorylated Thr187 in p27. Curr. Biol. 1999, 9:661-664.
107. Vaid M., Prasad R., Sun Q., Katiyar S.K. Silymarin targets beta-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS ONE 2011, 6:e23000.
108. Wang Y., Dai D.L., Martinka M., Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res. 2007, 13:4111-4116.
109. Wang Z., Inuzuka H., Zhong J., Wan L., Fukushima H., Sarkar F.H., Wei W. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012, 586:1409-1418.
110. Wei D., Sun Y. Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes Cancer 2010, 1:700-707.
111. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
112. Woenckhaus C., Maile S., Uffmann S., Bansemir M., Dittberner T., Poetsch M., Giebel J. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol. Histopathol. 2005, 20:501-508.
113. Wolter M., Scharwachter C., Reifenberger J., Koch A., Pietsch T., Reifenberger G. Absence of detectable alterations in the putative tumor suppressor gene BTRC in cerebellar medulloblastomas and cutaneous basal cell carcinomas. Acta Neuropathol. 2003, 106:287-290.
114. Wu K., Fuchs S.Y., Chen A., Tan P., Gomez C., Ronai Z., Pan Z.Q. The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol. Cell. Biol. 2000, 20:1382-1393.
115. Yang D., Li L., Liu H., Wu L., Luo Z., Li H., Zheng S., Gao H., Chu Y., Sun Y., Liu J., Jia L. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ. 2013, 20:235-247.
116. Ye Y., Rape M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 2009, 10:755-764.
117. Zhang G., Li G. Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS ONE 2012, 7:e45037.
118. Zhang H., Kobayashi R., Galaktionov K., Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995, 82:915-925.
119. Zhao Y., Sun Y. Cullin-RING ligases (CRLs) as attractive anti-cancer targets. Curr. Pharm. Des 2012, PMID:23151137.
120. Zhao Y., Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia 2012, 14:360-367.
121. Zhao Y., Xiong X., Jia L., Sun Y. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis. 2012, 3:e386.
122. Zhao Y., Xiong X., Sun Y. DEPTOR, an mTOR Inhibitor, is a physiological substrate of SCFβTrCP E3 ubiquitin ligase and regulates survival and autophagy. Mol. Cell 2011, 44:304-316.
123. Zheng N., Schulman B.A., Song L., Miller J.J., Jeffrey P.D., Wang P., Chu C., Koepp D.M., Elledge S.J., Pagano M., Conaway R.C., Conaway J.W., Harper J.W., Pavletich N.P. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002, 416:703-709.